BE655242A - - Google Patents

Info

Publication number
BE655242A
BE655242A BE655242DA BE655242A BE 655242 A BE655242 A BE 655242A BE 655242D A BE655242D A BE 655242DA BE 655242 A BE655242 A BE 655242A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BE655242A publication Critical patent/BE655242A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38Nitrogen atoms
    • C07D231/42Benzene-sulfonamido pyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44Oxygen and nitrogen or sulfur and nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE655242D 1963-11-05 1964-11-04 BE655242A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH1359863 1963-11-05
CH1210364 1964-09-17

Publications (1)

Publication Number Publication Date
BE655242A true BE655242A (en) 1965-05-04

Family

ID=25709624

Family Applications (1)

Application Number Title Priority Date Filing Date
BE655242D BE655242A (en) 1963-11-05 1964-11-04

Country Status (5)

Country Link
BE (1) BE655242A (en)
DE (1) DE1467832A1 (en)
FR (2) FR3797M (en)
GB (1) GB1054278A (en)
NL (1) NL6412822A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013046041A1 (en) * 2011-09-30 2013-04-04 Synovo Gmbh Pyridinylpyrazoles for use as kinase modulators for the treatment of cancer
WO2014111356A1 (en) 2013-01-17 2014-07-24 F. Hoffmann-La Roche Ag Oxytocin receptor agonists for the treatment of cns diseases

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3503609A1 (en) * 1985-02-02 1986-08-07 Bayer Ag, 5090 Leverkusen 5-SULPHONAMIDO-1-ARYL-PYRAZOLE
RU2579515C1 (en) * 2014-12-29 2016-04-10 Федеральное государственное бюджетное образовательное учреждение высшего образования "Сибирский государственный технологический университет" (СибГТУ) Alkoxymethyl-substituted 1h-4-aminopyrazoles

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013046041A1 (en) * 2011-09-30 2013-04-04 Synovo Gmbh Pyridinylpyrazoles for use as kinase modulators for the treatment of cancer
US9416123B2 (en) 2011-09-30 2016-08-16 Synovo Gmbh Kinase modulators for the treatment of cancer
WO2014111356A1 (en) 2013-01-17 2014-07-24 F. Hoffmann-La Roche Ag Oxytocin receptor agonists for the treatment of cns diseases
CN104936593A (en) * 2013-01-17 2015-09-23 霍夫曼-拉罗奇有限公司 Oxytocin receptor agonists for the treatment of CNS diseases
US9751870B2 (en) 2013-01-17 2017-09-05 Hoffman-La Roche Inc. Oxytocin receptor agonists for the treatment of CNS diseases
CN104936593B (en) * 2013-01-17 2018-05-18 霍夫曼-拉罗奇有限公司 For treating the oxytocin receptor agonist of CNS diseases

Also Published As

Publication number Publication date
FR4034M (en) 1966-03-28
DE1467832A1 (en) 1968-11-28
NL6412822A (en) 1965-05-06
FR3797M (en) 1965-12-27
GB1054278A (en) 1967-01-11

Similar Documents

Publication Publication Date Title
AR142945A1 (en)
FR4034M (en)
AT260747B (en)
FR4303M (en)
BE642371A (en)
BE627012A (en)
BE31062A (en)
BE627172A (en)
BE645161A (en)
BE645063A (en)
BE644971A (en)
BE644899A (en)
BE644122A (en)
BE643838A (en)
BE643779A (en)
BE643575A (en)
BE643487A (en)
BE643003A (en)
BE642934A (en)
BE642215A (en)
BE641615A (en)
BE637196A (en)
BE637066A (en)
BE634238A (en)
BE654924A (en)